Categories: NewsPharmaceutical

BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Ahti Paananen

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 31 August 2022 16.00 (CEST)

BBS Bioactive Bone Substitutes Oyj – Managers’ Transactions

____________________________________________

Person subject to the notification requirement

Name: Paananen, Ahti

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20220826083437_4

____________________________________________

Transaction date: 2022-06-17

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

Transaction details

(1): Volume: 166,689 Unit price: 1.3 EUR

Aggregated transactions

(1): Volume: 166,689 Volume weighted average price: 1.3 EUR

____________________________________________

Transaction date: 2022-06-20

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522909

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 20,836 Unit price:  EUR

Aggregated transactions

(1): Volume: 20,836 Volume weighted average price:  EUR

____________________________________________

Transaction date: 2022-06-20

Venue not applicable

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000522891

Nature of the transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 20,836 Unit price:  EUR

Aggregated transactions

(1): Volume: 20,836 Volume weighted average price:  EUR

For more information:

Ilkka Kangasniemi, CEO,
tel. +35840 7080307, e-mail: ilkka.kangasniemi@bbs-artebone.fi

Liisa Hukka, CFO,
tel. +35840 0611038, e-mail: liisa.hukka@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB, tel. +46 70 551 67 29, info@certifiedadviser.se

BBS in brief

BBS-Bioactive Bone Substitutes is a health technology company that started operations in 2003. We have developed a new product for the treatment of severe bone fractures and lumber problems. Our goal is to provide a new generation of medical products for the treatment of bone damage in orthopaedic surgery. In the pharmaceutical sector, development and research requires perseverance and courage to develop new things. We have evidence of this for over 20 years. Our activities are characterised by top expertise, innovation and employees who are enthusiastic and committed to their work. The ARTEBONE ® in the final stages of product development, and we are looking for a CE marking that enables commercialisation in the EU. We are a company in Oulu with a pharmaceutical factory permit in Reisjärvi.

BBS-Bioactive Bone Substitutes Oyj:n shares have been listed in Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

More information: www.bbs-artebone.fi

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

3 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

4 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

4 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

5 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

7 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

7 hours ago